Advertisement

Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px
Document › Details

Noxxon Pharma N.V.. (1/4/17). "Press Release: Noxxon Pharma Licenses and Assigns Preclinical Spiegelmer Programs to Aptarion. Noxxon Continues Transition to Clinical Oncology Company". Berlin.

Organisations Organisation Noxxon Pharma N.V. (Alternext Paris: ALNOX)
  Group Noxxon (Group)
  Organisation 2 Aptarion Biotech AG
Products Product Spiegelmer® technology
  Product 2 Spiegelmer® product
Index terms Index term Aptarion Biotech–Noxxon: Spiegelmer technology, 201701 acquisition techn + preclinical assets + lab assets from Noxxon for cash + royalties + shares
  Index term 2 Aptarion Biotech–Noxxon: investment, 201701 Noxxon receives Aptarion shares as part of transfer of preclinical assets to Aptarion
Persons Person Mangasarian, Aram (Noxxon 201005 CBO before Novexel since 200511 VP BusDev before ExonHit VP BusDev)
  Person 2 Klußmann, Sven (Aptarion Biotech 201608– CEO before Noxxon CSO)
     


NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion.

NOXXON has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer® technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.

“This agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed.” commented Aram Mangasarian, CEO of NOXXON.


For more information, please contact:

NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 2470
amangasarian@noxxon.com

NewCap
Florent Alba
Tel. +33 (0) 1 44 71 98 55
falba@newcap.fr


About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com

   
Record changed: 2017-01-17

Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px

More documents for Noxxon (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpq




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wptb Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px